HONG KONG (Reuters) – China Meheco Group Co Ltd said on Wednesday it signed an agreement with Pfizer on importing and distributing the pharmaceutical firm’s oral COVID-19 treatment product Paxlovid in mainland China.
The agreement is valid until Nov.30, 2023, China Meheco said in a filing to the Shanghai stock exchange.
Paxlovid, which was approved by China in February, has been available through hospitals to treat high-risk patients in several provinces, Chinese media Yicai reported in March.
(Reporting by Meg Shen and Ella Cao; Editing by Alison Williams)
